Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed, 73 citations in OpenAlex.

1. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
   Trial
2. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Antimicrobial agents and chemotherapy · 2008
   Trial
3. New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.Journal of clinical medicine · 2023
   Review
4. Ceftobiprole versus daptomycin inFuture microbiology · 2020
   Article
5. Ceftobripole: Experience in staphylococcal bacteremia.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019
   Review
6. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.Antimicrobial agents and chemotherapy · 2015
   Article
7. Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model.Antimicrobial agents and chemotherapy · 2012
   Article
8. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2012
   Article
9. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Antimicrobial agents and chemotherapy · 2012
   Article
10. In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2011
    Article
11. Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Therapeutics and clinical risk management · 2010
    Article
12. Community-associated meticillin-resistant Staphylococcus aureus.Lancet (London, England) · 2010
    Review
13. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2010
    Article
14. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.Clinical microbiology reviews · 2010
    Review
15. Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.Infection and drug resistance · 2010
    Article
16. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2010
    Article
17. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.Antimicrobial agents and chemotherapy · 2007
    Article
18. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.Antimicrobial agents and chemotherapy · 2007
    Article
19. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.Antimicrobial agents and chemotherapy · 2007
    Article
20. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2005
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as